Dr Dana Goldman Discusses Determing Value for Breakthrough Therapies

Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.

For example, there is value in curing a disease because it not only impacts the patient but also anyone the patient may have come in contact with, including caregivers and family members.

“We need to figure out how all these ancillary sources of value are affected and in particular who should pay for them as well,” Dr Goldman says.